Brighthaven Ventures bhvpharma.com


Brighthaven Ventures, dba BHV Pharma, is developing a novel, best in class, Sodium Glucose Transporter 2 (SGLT2) inhibitor indicated for Type 2 Diabetes and NASH. Remogliflozin has been dosed in over 800 subjects in over 20 clinical trials. In 12-week phase 2b studies in type 2 diabetics, remogliflozin lowered HbA1c greater than 1% and demonstrated a best in class side-effect profile. Remogliflozin is the only positively differentiated SGLT2 approved or in development with best in class efficacy...Show all

Brighthaven Ventures, dba BHV Pharma, is developing a novel, best in class, Sodium Glucose Transporter 2 (SGLT2) inhibitor indicated for Type 2 Diabetes and NASH. Remogliflozin has been dosed in over 800 subjects in over 20 clinical trials. In 12-wee...Show all

Company (Merged)

Phone: 919-904-4248

Fax:

P.O. Box 13765
3200 East Hwy 54
Durham, 27709
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Brighthaven Ventures $0M Oct 1, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Brighthaven Ventures Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)